Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale-New Haven Hospital, New Haven, Connecticut, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Local Institution - 0007, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Columbia University Irving Medical Center, New York, New York, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Local Institution - 0009, Fairfax, Virginia, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Local Institution - 0017, Marseille, Bouches-du-Rhône, France
Local Institution - 0018, Paris, France
Local Institution - 0022, Toulouse, France
Hospital Clínic de Barcelona, Barcelona, Catalunya [Cataluña], Spain
Hospital Universitario Virgen Del Rocio, Seville, Spain
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb